Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Next Previous
Search
Trial Profile

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMvigor210
  • Sponsors Roche

    • Most Recent Events

    • 06 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2022 Results of a study assessing clinical activity and molecular correlates of resistance to ICI in patients with metastatic urothelial carcinoma, focusing on liver metastasis from; patients received pembrolizumab (JUOG cohort), patients who were treated with atezolizumab (IMvigor210 cohort), and mUC patients who had metastatic samples available published in the Cancer Immunology Immunotherapy
    • 23 Aug 2022 Results deriving data from IMvigor210 determining whether the integration of CD39 and traditional biomarkers could improve the prediction of responsiveness to PD-L1 blockade and platinum-based chemotherapy published in the British Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top